A Phase Ib Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab, To Patients With Advanced Platinum-sensitive Ovarian Cancer
Phase of Trial: Phase I
Latest Information Update: 30 Nov 2019
Price : $35 *
At a glance
- Drugs Atezolizumab (Primary) ; Cobimetinib (Primary) ; Niraparib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Genentech; Roche
- 03 Jul 2019 Planned End Date changed from 24 Nov 2022 to 15 Dec 2022.
- 03 Jul 2019 Planned primary completion date changed from 24 Nov 2022 to 15 May 2020.
- 04 Feb 2019 Status changed from not yet recruiting to recruiting.